Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared a post on X:
“ORCHARD study.
Now I assume EGFR patients will make it to 4+lines.
Very manageable toxicity with DatoDXD. ”
Title: Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
Authors: J.W. Riess, H.A. Yu, X. Le, A. Johannes de Langen, B. Chul Cho, Z. Piotrowska, L.E.L. Hendriks, A. Morabito, L. Bonanno, O. Terje Brustugun, T.O. Halvorsen, Y. Jung Kim, K.A. Marrone, Y. Shiraishi, J.W. Goldman, H. Ambrose, P.E. Smith, P.G. FraenkeI, K. Ho Tang, J.M. Lehman, S.B. Goldberg
Other articles about NSCLC on OncoDaily.